Literature DB >> 7721271

Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper.

T Rosén1, G Johannsson, J O Johansson, B A Bengtsson.   

Abstract

Growth hormone deficiency (GHD) in adults is now recognized as a specific clinical syndrome with characteristic symptoms and signs. Thus, the patients are overweight, have an abnormal body composition (excess body fat and a decrease in the extracellular water volume) and a low bone mineral content compared to normals. Furthermore, the GHD patients have lipid abnormalities, decreased insulin sensitivity and a decreased fibrinolysis. Finally, the 'quality of life' is low in terms of energy and social life. Short- and long-term studies with recombinant human GH (rhGH) treatment have shown normalization of body composition, increase in the lipid pattern and marked improvement of the psychological well-being. The treatment seems safe with no serious side effects reported. In analogy with other hormonal replacement therapies, the rhGH dose should be individualized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721271     DOI: 10.1159/000184245

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

1.  Metabolic effects of discontinuing growth hormone treatment.

Authors:  F J Cowan; W D Evans; J W Gregory
Journal:  Arch Dis Child       Date:  1999-06       Impact factor: 3.791

2.  Growth hormone for adults.

Authors:  D R Hadden
Journal:  J R Soc Med       Date:  1997-03       Impact factor: 5.344

Review 3.  Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.

Authors:  A K Mantel-Teeuwisse; J M Kloosterman; A H Maitland-van der Zee; O H Klungel; A J Porsius; A de Boer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.

Authors:  R H Böger; C Skamira; S M Bode-Böger; G Brabant; A von zur Muhlen; J C Frolich
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 5.  [Hypophyseal coma].

Authors:  B L Herrmann; K Mann
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.